CTRI/2009/091/000423已完成3 期
A randomised Phase III clinical study of bevacizumab pluscapecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed during first-line docetaxel plus bevacizumab therapy
F HoffmannLa Roche0 个研究点目标入组 360 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •adult patients, greater or equal to18 years of age;
- •-HER2-negative metastatic breast cancer
- •-candidates for taxane-based chemotherapy;
- •-ECOG performance status of 0 or 1.
排除标准
- •-previous chemotherapy for metastatic breast cancer;
- •-prior adjuvant/neo-adjuvant chemotherapy within 6 months prior to study;
- •-prior radiotherapy for treatment of metastatic disease;
- •chronic daily treatment with aspirin (325 mg/day) or clopidogrel(>75mg/day).
研究者
相似试验
进行中（未招募）
不适用
A randomized phase III clinical study of bevacizumab plus capecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed during first-line docetaxel plus bevacizumab therapy. - IMELDAHER2-negative metastatic breast cancer that has not progressed during first-line docetaxel plus bevacizumab therapy.MedDRA version: 12.1Level: LLTClassification code 10055113Term: Breast cancer metastaticEUCTR2008-006872-31-ITF. Hoffmann - La Roche Ltd420
进行中（未招募）
1 期
A randomized phase III clinical study of bevacizumab plus capecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed during first-line docetaxel plus bevacizumab therapy. - IMELDAHER2-negative metastatic breast cancer that has not progressed during first-line docetaxel plus bevacizumab therapy.MedDRA version: 9.1Level: LLTClassification code 10055113Term: Breast cancer metastaticEUCTR2008-006872-31-FRF. Hoffmann-La Roche Ltd287
尚未招募
3 期
A study to compare bevacizumab drug in low dose versus standard dose in lung cancer patientsCTRI/2023/06/054174Tata Memorial Hospital
进行中（未招募）
不适用
Phase II randomized study of intravenous bevacizumab with sequential versus concurrent oral vinorelbine plus capecitabine in patients with locally advanced or recurrent breast cancer with lymphangitic spread to the chest wall. - NDlocally advanced or recurrent breast cancer with lymphangitic spread to the chest wall.MedDRA version: 9.1Level: LLTClassification code 10006279Term: Breast neoplasmEUCTR2006-002152-16-ITISTITUTO EUROPEO DI ONCOLOGIA
进行中（未招募）
3 期
AMBITION studyBreast CancerJPRN-jRCT2031200335Yonemori Kan280